B+
Bull case
20%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
IBIO
iBioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Successful IND progress and reassuring IBIO-600 human data could strengthen the case for iBio's obesity body-composition pipeline. The October IBIO-610 evidence remains preclinical and came from a small primate study.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Higher R&D spending and possible equity issuance create dilution risk. The company has an up-to-$100 million at-the-market sales agreement; the October 19 filing also reported an increase in authorized common shares from 275 million to 500 million, which does not itself mean shares were issued. [#SEC-8K-2026-08-28] [#8-K-2026-10-19] (SEC earnings exhibit; SEC October filing)
Momentum
96
Value
56
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.65 · Bull $1.20 · Bear $0.35Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.60
Why
Momentum96 · Δ7d -
Value56 · Δ7d -0.2
Sentiment70 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Higher R&D spending and possible equity issuance create dilution risk. The company has an up-to-$100 million at-the-market sales agreement; the October 19 filing also reported an increase in authorized common shares from 275 million to 500 million, which does not itself mean shares were issued. [#SEC-8K-2026-08-28] [#8-K-2026-10-19] (SEC earnings exhibit; SEC October filing)
- • IBIO-600 safety, pharmacokinetics and efficacy remain unproven despite progress through single-ascending-dose cohorts. [#SEC-8K-2026-08-28]
- • Clinical translation, trial timing and funding needs remain uncertain.
Catalyst clock
2026-12-31
IBIO-610 IND-equivalent filing
Lead driver: Sentiment · See AI snapshot
Momentum
96
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-2.0
Sentiment
70
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.6 / Value 56.3 / Sentiment 70.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$43.68M
Beta
1.26
Shares Out
60.85M
P/E (TTM) · Derived
-2.3
P/S (TTM)
84.55
P/FCF (TTM) · Derived
-1.44
Rev YoY
-100.0%
EPS YoY
-86.9%
Gross Margin
-255.0%
Op Margin
-4089.4%
Net Debt
-$5.07M
Current Ratio
11.88
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data